impress mdt recent string beat felt
share price gotten away us near despit compel
rel valuat concern tough comp
recent new cvg concern cautionari languag around tax
propos push share back attract level view
risk around dcb lvad tax feel
number could offer upsid think management may
overli cautiou feel potenti share reward
base qualiti result upcom quarter paclitaxel concern
eas tax chang materi enthusiasm around low-risk
expans post march would buy share
cvg issu wont last forev may overdon confer
last week management trim segment outlook slowdown
dcb market paclitaxel concern chang lvad
market competit abbott neutral believ
other present addit data show paclitaxel safe
fda could put statement eas fear eu
eventu cycl chang transplant list
return lvad growth think number met may
even beatabl
pipelin broad rich though dont forese materi
needle-mov next quarter point broad-bas
pipelin launch support least top-lin growth
spine neurovascular leadless pace diabet
street would pleas robot launch sure
medtron true appetit may hurt surgic margin
think least launch someth ou next two year
share could move upward
valuat pt base mo ep estim
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
high-level takeaway meet
confer san francisco last week spent
time medtron ceo omar ishrak cfo karen parkhil high
level pleas recent result believ long term
strong growth continu come meet think
manag conserv impact worri paclitaxel
tax chang recent physician publish report potenti
higher mortal signal paclitaxel use seen
slowdown order account frankli told would
back use hard distinguish normal holiday slowdown vs
actual concern either way like other work
fda would surpris fda statement safeti frankli
think concern die manag feel confid
devic safe data demonstr
feel cut mdt growth outlook area well concern
propos tax chang could overdon manag mention
unclear much implement chang mitig tax chang
temporari view would wouldnt tri make
chang stem neg impact suspect neither dcb issu
tax hit quit much recent commentari might indic
could provid upsid
robot manag continu state devic launch time
outsid give timelin believ medtron
build robot wonder dedic launch given numer
delay think overal dollar pie surgeri unlik chang thu
robot could hurt margin must robot need keep share
view may look launch sell mani possibl
frankli know strategi believ someth launch
share move higher even limit launch first
 compani look market potenti synergi
manag state best type one like recent close
mazor purchas wherein pour market fuel devic
drive system sale sale drive dispos spine
hardwar compani alreadi product major market share
area attract one reduc diseas burden offer
econom benefit share hospit case
tyrx absorb antibacteri envelop cardiac implant devic
expect addit keep ad top-lin growth though
expect anoth transform deal like covidien anecdot ceo
laugh describ mazor expens covidien expens
share current trade consensu next twelv month ep
estim repres discount four-year histor averag
discount basket large-cap diversifi player grow
revenu rang find compel
exhibit medtron price-to-earnings ntm earn
price-to-earnings valuat ntm earn
exhibit comp tabl large-cap peer
light specif issu within drug-coat balloon lvad
trim segment estim cvg group model segment
 growth full year
model cvg growth vs previous total compani
forecast growth believ
offset within rtg mitg keep total revenu stabl vs
prior expect though make chang oper margin
ntm johnsonjnjnot bdxnot scientificbsxbuy factset data btig estimatespr ex-amortcompanytickr ptpricemarket cap bev/salescagr
assumpt revenu tweak take ep estim outlin
also updat model includ contribut mazor
close decemb model growth
also keep oper margin estim steadi healthcar
confer last week manag caution exist tax propos
around treatment inter-compani expens debt etc could lead
neg bp impact tax rate model
up-tick result trim ep
invest thesi valuat
medtron rate buy pt base share trade
month ep estim target multipl similar share
histor averag although recent cvg product concern diminish
potenti quarterli beat near-term feel potenti
share reward paclitaxel concern eas neg tax
propos materi and/or enthusiasm around low-risk
expans within tavr market addit point broad-bas
pipelin launch support least top-lin growth
area spine neurovascular neuromodul leadless pace
diabet risk includ deterior cvg spine market robot
launch materi advers tax propos soft emerg
market margin degrad expans new busi line
competit slippag product timelin chang procedur
reimburs futur devic data fda use cash/m
bpsc growth bpsadj net bpsgross bpsebit bpssourc btig estim compani filingsnewold chang
medtron incom eproduct net y/i good gross total oper oper expens adj oper interest expens non-oper expense/ inc pre-tax incom adj net non-controlling adj net incom adjust ep share total net oper net product product product oper btig estim compani report
medtron revenu ecrm heart failur structur heart y/i peripher vascular total recast y/i vascular group y/i patient monitor recoveri y/i invas group y/i recast therapi recast therapi recast therapi recast therapi group y/i group y/i y/i oper y/i btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
